Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10612studies shown

Showing 3,073-3,084 of 10,612

Other study type icon

TerminatedNCT04577144

An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionObservationalOver 18 Years

Countries: United States
Sponsor: Indivior Inc.
Condition: Addiction

Behavioral study icon

TerminatedNCT04781166

An Online Intervention to Reduce Suicide prevention Among Persons With High Emotion-Related Impulsivity

This summary needs review. Please check the official study record and contact the research team for details.

Remote / online

SuicidalityBehavioralOver 13 Years

Countries: United States
Sponsor: University of California, Berkeley
Condition: Suicidality

Behavioral study icon

CompletedNCT01587118

An Open Label Study of Adjunctive Asenapine for PTSD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

PTSDBehavioralFrom 19 Years to 65 Years

Countries: United States
Sponsor: Lori Davis, MD
Condition: PTSD

Drug study icon

TerminatedNCT05254405

An Open Label Study of IV Brexanolone for PTSD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

PTSDDrugFrom 18 Years to 50 Years

Countries: United States
Sponsor: Donald Jeffrey Newport
Condition: PTSD

Drug study icon

CompletedNCT01646827

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 64 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

UnknownNCT04433858

Safety and Efficacy of Psilocybin for treatment-resistant depression

This study has an unknown status in the United States. It is testing safety and Efficacy of Psilocybin for treatment-resistant depression.

In United States

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Sheppard Pratt Health System
Condition: Depression

Drug study icon

CompletedNCT01666119

Safety study of BEMA® Buprenorphine NX in Addiction

This study is completed in the United States. It is testing BEMA® Buprenorphine NX for Addiction.

In United States

AddictionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: BioDelivery Sciences International
Condition: Addiction

Drug study icon

CompletedNCT01038128

An Open Label study of Memantine in the Treatment of Eating disorders and Body Dysmorphic Disorder

This summary needs review. Please check the official study record and contact the research team for details.

In United States

Eating disordersDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Mclean Hospital
Condition: Eating disorders

Device study icon

CompletedNCT02640950

An Open Label study of TMS Therapy for Depression in bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

In United States

Bipolarity, DepressionDeviceOver 18 Years

Countries: United States
Sponsor: Sheppard Pratt Health System
Condition: Bipolarity, Depression

Drug study icon

TerminatedNCT01139125

An Open study of Cysteamine Treatment in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 60 Years

Countries: United States
Sponsor: Augusta University
Condition: Schizophrenia

Drug study icon

CompletedNCT00228059

Licarbazepine for manic episodes in bipolarity type I

This study is completed in the United States. It is testing licarbazepine for manic episodes in bipolarity type I.

In United States

BipolarityDrugFrom 18 Years to 70 Years

Countries: United States
Sponsor: Novartis
Condition: Bipolarity

Drug study icon

Enrolling By InvitationNCT07161700

Safety study of SPT-300 (GlyphAllo) in depression

This study is enrolling by invitation in the United States, in Bulgaria, in Czechia, .... It is testing SPT-300 (GlyphAllo) for depression.

In United States

DepressionDrugFrom 18 Years to 66 Years

Countries: United States, Bulgaria, Czechia, ...
Sponsor: Seaport Therapeutics
Condition: Depression

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.